American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor
BLAUVELT, N.Y., Nov. 19 Dr. Mate Hidvegi, inventor of Avemar fermented wheat germ extract, responds to a press release issued on November 17 by Biropharma Kft, discrediting the Hungarian company for making false and self-serving statements about its U.S. competitor American BioSciences.
Dr. Hidvegi stated from his office in Budapest, Hungary:
"The Biropharma claim that research on Avemar does not apply to AveULTRA, www.aveultra.com, is misleading. Avemar has always been manufactured according to methods which I developed and patented. American BioSciences utilizes processes covered by my most recent pending patent. State of the art technology more precisely controls process times and temperatures creating a better quality fermented wheat germ extract. Independent analysis shows that Avemar made by Biropharma and sold under the brand name Ave(TM) and Avemar made by American BioSciences and sold under the brand name AveULTRA, are virtually identical, confirmed by the technique of HPLC finger printing. Furthermore, independent comparison by biological assays in both cell lines and animal models shows the American BioSciences product has superior effects," he said. According to Dr. Hidvegi, these data are being prepared for publication in a peer-reviewed scientific journal.
AveULTRA, newly introduced by American BioSciences, contains the same amount of Avemar fermented wheat germ actives per daily use packet as Ave and is three times more concentrated, with 99 percent less non-active ingredients and no sugar. AveULTRA supports cell metabolic regulation, promotes immune system modulation, and maintains healthy cellular and humoral (Th1/Th2) immune balance. It promotes optimal NK cell targeting ability and the coordinated response of macrophages, B-cells and T-Cells.
"AveULTRA is a huge improvement over the original Ave," said Cincinnati OB/GYN Maureen Pelletier, MD, CCN. "My patients like the concentrated formula, as well as the improved taste."
For more information, contact Dean Draznin Communications, Inc.
SOURCE American BioSciences
You May Also Like